165 related articles for article (PubMed ID: 38009232)
21. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
[TBL] [Abstract][Full Text] [Related]
22. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic applications of PARP inhibitors in ovarian cancer.
Xie H; Wang W; Xia B; Jin W; Lou G
Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
26. Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G; Gigli F; Parma G; Lapresa M; Derio S; Palaia I; Colombo N
Int J Gynecol Cancer; 2023 Apr; 33(4):598-606. PubMed ID: 36707087
[TBL] [Abstract][Full Text] [Related]
27. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
Washington CR; Moore KN
Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
[TBL] [Abstract][Full Text] [Related]
28. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
29. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
Hinchcliff E; Chelariu-Raicu A; Westin SN
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
[TBL] [Abstract][Full Text] [Related]
30. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
31. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
32. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
33. [PARP inhibitors - A better selection of patients].
Senglet M; Berthod G; Courtes MG; Anchisi S; Membrez V; Nay Fellay C
Rev Med Suisse; 2023 May; 19(827):932-937. PubMed ID: 37195105
[TBL] [Abstract][Full Text] [Related]
34. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
36. The development of PARP as a successful target for cancer therapy.
Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
[TBL] [Abstract][Full Text] [Related]
37. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
38. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
39. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
Miller RE; El-Shakankery KH; Lee JY
J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
